Cargando…
Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy
The elevation of SMN transcript and protein level remains the principal aim of SMA therapy. Still, there is no standard molecular biomarker for the assessment of its efficacy. In the current study, we tested three methods of SMN transcript level measurement using real-time RT-PCR, quantitative fluor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602009/ https://www.ncbi.nlm.nih.gov/pubmed/36292797 http://dx.doi.org/10.3390/genes13101911 |
_version_ | 1784817206721249280 |
---|---|
author | Maretina, Marianna Egorova, Anna Lanko, Kristina Baranov, Vladislav Kiselev, Anton |
author_facet | Maretina, Marianna Egorova, Anna Lanko, Kristina Baranov, Vladislav Kiselev, Anton |
author_sort | Maretina, Marianna |
collection | PubMed |
description | The elevation of SMN transcript and protein level remains the principal aim of SMA therapy. Still, there is no standard molecular biomarker for the assessment of its efficacy. In the current study, we tested three methods of SMN transcript level measurement using real-time RT-PCR, quantitative fluorescent RT-PCR, and a semiquantitative RT-PCR gel densitometric assay. We examined several potential mRNA-based biomarkers and examined their sensitivity and reliability by comparing the obtained values in peripheral blood mononuclear cells of SMA patients, SMA carriers, and healthy individuals. We found that the mean percentage of full-length (FL-SMN) transcripts relative to the total sum of FL-SMN and exon 7-deleted (Δ7 SMN) transcripts detected by semiquantitative and quantitative fluorescence RT-PCR differed significantly between the three analyzed groups. The relevance of this biomarker was proven in an SMN2-targeting therapeutic experiment. We showed that the values of the biomarker changed significantly in SMA fibroblast cell cultures after treatment with therapeutic antisense oligonucleotides targeting the ISS-N1 site in intron 7 of the SMN2 gene. The obtained results indicate the convenience of using the mean percentage of FL-SMN transcripts determined by semiquantitative and quantitative fluorescence RT-PCR as a putative biomarker for the assessment of SMA therapy efficacy in vitro. |
format | Online Article Text |
id | pubmed-9602009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96020092022-10-27 Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy Maretina, Marianna Egorova, Anna Lanko, Kristina Baranov, Vladislav Kiselev, Anton Genes (Basel) Article The elevation of SMN transcript and protein level remains the principal aim of SMA therapy. Still, there is no standard molecular biomarker for the assessment of its efficacy. In the current study, we tested three methods of SMN transcript level measurement using real-time RT-PCR, quantitative fluorescent RT-PCR, and a semiquantitative RT-PCR gel densitometric assay. We examined several potential mRNA-based biomarkers and examined their sensitivity and reliability by comparing the obtained values in peripheral blood mononuclear cells of SMA patients, SMA carriers, and healthy individuals. We found that the mean percentage of full-length (FL-SMN) transcripts relative to the total sum of FL-SMN and exon 7-deleted (Δ7 SMN) transcripts detected by semiquantitative and quantitative fluorescence RT-PCR differed significantly between the three analyzed groups. The relevance of this biomarker was proven in an SMN2-targeting therapeutic experiment. We showed that the values of the biomarker changed significantly in SMA fibroblast cell cultures after treatment with therapeutic antisense oligonucleotides targeting the ISS-N1 site in intron 7 of the SMN2 gene. The obtained results indicate the convenience of using the mean percentage of FL-SMN transcripts determined by semiquantitative and quantitative fluorescence RT-PCR as a putative biomarker for the assessment of SMA therapy efficacy in vitro. MDPI 2022-10-20 /pmc/articles/PMC9602009/ /pubmed/36292797 http://dx.doi.org/10.3390/genes13101911 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maretina, Marianna Egorova, Anna Lanko, Kristina Baranov, Vladislav Kiselev, Anton Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title | Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title_full | Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title_fullStr | Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title_full_unstemmed | Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title_short | Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy |
title_sort | evaluation of mean percentage of full-length smn transcripts as a molecular biomarker of spinal muscular atrophy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602009/ https://www.ncbi.nlm.nih.gov/pubmed/36292797 http://dx.doi.org/10.3390/genes13101911 |
work_keys_str_mv | AT maretinamarianna evaluationofmeanpercentageoffulllengthsmntranscriptsasamolecularbiomarkerofspinalmuscularatrophy AT egorovaanna evaluationofmeanpercentageoffulllengthsmntranscriptsasamolecularbiomarkerofspinalmuscularatrophy AT lankokristina evaluationofmeanpercentageoffulllengthsmntranscriptsasamolecularbiomarkerofspinalmuscularatrophy AT baranovvladislav evaluationofmeanpercentageoffulllengthsmntranscriptsasamolecularbiomarkerofspinalmuscularatrophy AT kiselevanton evaluationofmeanpercentageoffulllengthsmntranscriptsasamolecularbiomarkerofspinalmuscularatrophy |